ArticleInvestigational new drugs2015
BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.
Article in Investigational new drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Rapid but nondurable response of aOncotarget · 2024Article
- Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution.International journal of molecular sciences · 2024Review
- Metastatic clear cell sarcoma of the pancreas: A rare case report.World journal of clinical cases · 2024Article
- Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives.International journal of molecular sciences · 2021Review
- Translating Molecular Profiling of Soft Tissue Sarcomas into Daily Clinical Practice.Diagnostics (Basel, Switzerland) · 2021Review
- A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy.Oncotarget · 2020Article
- BRAF mutation and its inhibitors in sarcoma treatment.Cancer medicine · 2020Review
- Translocation-Related Sarcomas.International journal of molecular sciences · 2018Review
- Identification of a novel MTAP-RAF1 fusion in a soft tissue sarcoma.Diagnostic pathology · 2018Article
- Preclinical Evaluation of Vemurafenib as Therapy for BRAFInternational journal of molecular sciences · 2018Article
- Molecular Diagnostics in Clinical Oncology.Frontiers in molecular biosciences · 2018Review
- Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.Journal of gastrointestinal cancer · 2016Article
- Targeting BRAF mutants in clear-cell sarcomas of soft tissue: beyond sarcoma or melanoma classification.Investigational new drugs · 2016Article
- Molecular targeted therapy for advanced or metastatic soft tissue sarcoma.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a patient with a metastatic relapse of clear cell sarcoma, whose tumor harbored BRAF V600E mutation. Standard chemotherapy with doxorubicin and ifosfamide failed to slow the disease progression. Subsequent administration of vemurafenib (960 mg twice a day) resulted in complete tumor response after 8 weeks of treatment. Literature data on the use of vemurafenib and dabrafenib in non-melanoma BRAF-mutated tumors are reviewed.
Indexed as
Identifiers
26286452What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.